- Home
- HBT vs ETNB Comparison
HBT vs ETNB Comparison
Compare HBT & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBT
- ETNB
- Stock Information
- Founded
- HBT 1920
- ETNB 2018
- Country
- HBT United States
- ETNB United States
- Employees
- HBT N/A
- ETNB N/A
- Industry
- HBT Major Banks
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- HBT Finance
- ETNB Health Care
- Exchange
- HBT Nasdaq
- ETNB Nasdaq
- Market Cap
- HBT 760.3M
- ETNB 773.7M
- IPO Year
- HBT 2019
- ETNB 2019
- Fundamental
- Price
- HBT $25.19
- ETNB $10.77
- Analyst Decision
- HBT Hold
- ETNB Strong Buy
- Analyst Count
- HBT 6
- ETNB 9
- Target Price
- HBT $24.17
- ETNB $31.43
- AVG Volume (30 Days)
- HBT 36.5K
- ETNB 3.5M
- Earning Date
- HBT 01-22-2025
- ETNB 02-27-2025
- Dividend Yield
- HBT 3.42%
- ETNB N/A
- EPS Growth
- HBT 9.18
- ETNB N/A
- EPS
- HBT 2.26
- ETNB N/A
- Revenue
- HBT $221,390,000.00
- ETNB N/A
- Revenue This Year
- HBT N/A
- ETNB N/A
- Revenue Next Year
- HBT $1.60
- ETNB N/A
- P/E Ratio
- HBT $11.01
- ETNB N/A
- Revenue Growth
- HBT N/A
- ETNB N/A
- 52 Week Low
- HBT $17.75
- ETNB $5.99
- 52 Week High
- HBT $25.35
- ETNB $16.63
- Technical
- Relative Strength Index (RSI)
- HBT 65.99
- ETNB 74.66
- Support Level
- HBT $23.33
- ETNB $9.16
- Resistance Level
- HBT $25.01
- ETNB $9.90
- Average True Range (ATR)
- HBT 0.78
- ETNB 0.83
- MACD
- HBT 0.26
- ETNB 0.41
- Stochastic Oscillator
- HBT 96.33
- ETNB 82.37
About HBT HBT Financial Inc.
HBT Financial Inc provides a comprehensive suite of business, commercial, wealth management, and retail banking products and services to individuals, businesses, and municipal entities throughout Central and Northeastern Illinois and Eastern Iowa. It operates through one reportable segment: community banking.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).